(ASRT) Assertio Therapeutics - Ratings and Ratios

Assertio Holdings, Inc. (NASDAQ: ASRT) is a pharmaceutical company that specializes in developing and commercializing various products for the US market. The companys product portfolio includes a range of medications for treating conditions such as rheumatoid arthritis, seizures, migraines, and pain management. Key products include INDOCIN, Sympazan, CAMBIA, SPRIX, Otrexup, and ROLVEDON, each targeting specific medical needs.

From a business perspective, Assertio Holdings has undergone significant changes, including a name change from Assertio Therapeutics, Inc. in May 2020. The company is headquartered in Lake Forest, Illinois, and operates within the pharmaceuticals industry, specifically within the GICS Sub Industry of Pharmaceuticals.

Analyzing the , we observe that the stocks Last Price is $0.71, with short-term moving averages (SMA20 and SMA50) indicating a positive trend, as the stock price is above both the SMA20 ($0.63) and SMA50 ($0.66). However, the long-term SMA200 ($0.92) suggests that the stock is currently trading below its longer-term average, potentially indicating a downtrend. The Average True Range (ATR) of 0.05 represents a 6.68% volatility, and the stock is currently trading between its 52-week high ($1.75) and low ($0.53). This technical analysis suggests a potential for volatility and a possible reversal if the stock can break through its SMA200.

Examining the , Assertio Holdings has a Market Cap of $62.22M USD, indicating a relatively small-cap company. The absence of a P/E ratio suggests that the company may not be profitable, or it may have negative earnings. However, the Forward P/E of 14.99 implies that analysts expect the company to become profitable in the future. The Return on Equity (RoE) of -16.66% indicates that the company is currently not generating profits for its shareholders.

Combining both technical and fundamental analysis, a potential forecast for ASRT could be that the stock may experience a short-term positive trend if it continues to trade above its short-term moving averages. However, the long-term downtrend and negative RoE are concerns. If the company can demonstrate profitability and improve its RoE, it could lead to a more positive outlook. Based on the current data, a potential price target could be a move towards the SMA200 at $0.92, representing a potential upside of around 30% from current levels. However, this would require a significant improvement in the companys fundamental performance and a reduction in volatility.